Merus NV Quote - MRUS

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

46.07

Bid

43.50

Ask

48.10

Volume

0.00 Day's Range 0.00

37.77 52 Week Range 61.61

Market Cap

3.183B

Previous Close

46.07

Open

Last Trade

45.53

Last Trade Time

03:09:34

Financial Volume

VWAP

Average Volume (3m)

631,755

Shares Outstanding

69,090,469

Dividend Yield

PE Ratio

0.00

Earnings Per Share (EPS)

Revenue

43.95M

Net Profit

-154.94M

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector

Gen Med & Surgical Hospitals

Industry

Gen Med & Surgical Hospitals

Website

www.merus.nl

Headquarters

Utrecht, Utrecht, Nld

Founded

Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was US$46.07. Over the last year, Merus NV shares have traded in a share price range of US$ 37.77 to US$ 61.61.

Merus NV currently has 69,090,469 shares outstanding. The market capitalization of Merus NV is US$3.18 billion.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Merus to Present at Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a...

Form 4 - Statement of changes in beneficial ownership of securities

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.3405	-0.733670182394	46.4105	47.42	43.58	727476	45.56041124	CS
4	4.77	11.5496368039	41.3	48.095	39.78	664857	44.96220223	CS
12	3.35	7.84176029963	42.72	48.095	37.77	631755	42.81090394	CS
26	-4.25	-8.44594594595	50.32	55.39	37.77	576940	45.78962784	CS
52	-0.42	-0.903420090342	46.49	61.61	37.77	680477	49.03019052	CS
156	19.16	71.2002972873	26.91	61.61	12.03	461132	36.37467859	CS
260	29.21	173.25029656	16.86	61.61	10.18	356573	33.22725172	CS

MRUS - Frequently Asked Questions (FAQ)

What is the current Merus NV share price?

The current share price of Merus NV is US$ 46.07

How many Merus NV shares are in issue?

Merus NV has 69,090,469 shares in issue

What is the market cap of Merus NV?

The market capitalisation of Merus NV is USD 3.18B

What is the 1 year trading range for Merus NV share price?

Merus NV has traded in the range of US$ 37.77 to US$ 61.61 during the past year

What is the reporting currency for Merus NV?

Merus NV reports financial results in USD

What is the latest annual turnover for Merus NV?

The latest annual turnover of Merus NV is USD 43.95M

What is the latest annual profit for Merus NV?

The latest annual profit of Merus NV is USD -154.94M

What is the registered address of Merus NV?

The registered address for Merus NV is UPPSALALAAN 17, UTRECHT, UTRECHT, 3584 CT

What is the Merus NV website address?

The website address for Merus NV is www.merus.nl

Which industry sector does Merus NV operate in?

Merus NV operates in the GEN MED & SURGICAL HOSPITALS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CKPTCheckpoint Therapeutics Inc	US$ 4.15 (68.02%)	325.72k
ICONIcon Energy Corporation	US$ 0.2499 (48.05%)	2.98M
STSSSharps Technology Inc	US$ 0.4099 (38.15%)	2.39M
BCMLBayCom Corporation	US$ 32.40 (23.76%)	1
SNOASonoma Pharmaceuticals Inc	US$ 2.455 (23.37%)	42.16k
BTOGBit Origin Ltd	US$ 0.42 (-32.26%)	522.36k
ABLVAble View Global Inc	US$ 1.185 (-31.90%)	20.58k
BZAIBlaize Holdings Inc	US$ 2.29 (-30.61%)	15
XMTRXometry Inc	US$ 19.01 (-22.82%)	3
SUNESUNation Energy Inc	US$ 0.3089 (-22.48%)	298.66k
ICONIcon Energy Corporation	US$ 0.2499 (48.05%)	2.98M
STSSSharps Technology Inc	US$ 0.4099 (38.15%)	2.39M
SHViShares Short Treasury Bond ETF	US$ 110.21 (0.01%)	1.07M
NVNINVNI Group Ltd	US$ 0.325 (22.18%)	983.89k
BTOGBit Origin Ltd	US$ 0.42 (-32.26%)	522.36k